Actively Recruiting
COMPASS Study for Metastatic Castration-resistant Prostate Cancer
Led by Duke University · Updated on 2026-05-04
48
Participants Needed
3
Research Sites
125 weeks
Total Duration
On this page
Sponsors
D
Duke University
Lead Sponsor
P
Prostate Cancer Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-201 in order to participate in this study. The purpose of this companion study is to learn more about biomarkers, particularly a biomarker called CXCR2, and investigate if CXCR2 can predict who will receive benefit from the SYNERGY-201 drug combination. This study will also investigate how CXCR2 and other biomarkers change over time when participants receive the SYNERGY-201 drug combination. CXCR2 is of particular interest because the SYNERGY-201 drug, SX-682, inhibits CXCR2. After participants provide consent, blood samples will be collected for research purposes at three SYNERGY-201 visits (Baseline, Cycle 3 Day 1 and End of Study Drug). Up to 20 participants will also receive tumor biopsies at the Baseline and SYNERGY-201 Cycle 3 Day 1 visits. Clinical and study data collected as part of SYNERGY-201 will also be used for this study.
CONDITIONS
Official Title
COMPASS Study for Metastatic Castration-resistant Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to provide written informed consent for this study and HIPAA authorization for the release of personal health information.
- Age over 18 years.
- Currently participating in the SYNERGY-201 clinical trial.
You will not qualify if you...
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the study results.
- History or current evidence of any condition, therapy, or laboratory abnormality that might interfere with full participation in the study.
- History or current evidence of any condition, therapy, or laboratory abnormality that is not in the participant's best interest to participate, as judged by the treating investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94158
Actively Recruiting
2
Rogel Cancer Center
Ann Arbor, Michigan, United States, 48109-2800
Actively Recruiting
3
Duke University
Durham, North Carolina, United States, 27705
Actively Recruiting
Research Team
K
Kellie Shobe, MS, BSN, RN
CONTACT
M
Monika Anand, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here